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VALUE BASED PRICING: WHAT IS THE FUTURE FOR PATIENT ACCESS
SCHEMES?
Loveman CM, Mallinson M, Areteou T, White R
Double Helix Consulting, London, UK
OBJECTIVES: In the face of universal budget restrictions, pricing of pharmaceuti-
cals remains a divisive subject. TheUS government is increasing its involvement in
healthcare provision and insurers will have more budget pressures due to in-
creased coverage. In the UK, the government has proposed a value based pricing
approach which will potentially increase the availability of new drugs. The objec-
tive of this research is to better understand the future outlook for patient access
schemes (PAS) in achieving affordable budget impact whilst not restricting patient
access. METHODS: 40 telephone interviews were undertaken with payers in the
UK, US and Taiwan representing government agencies, HTA groups and insurers.
We asked interviewees about their perceptions of PAS policies to provide required
value evidence, improve affordability, strategies that could be used by manufac-
turers and likely future changes. RESULTS: Results demonstrated that manufac-
turers will aim for a particular price or price threshold; if this is not accepted by
payers, outcome-based schemes or other flexible pricing arrangements would be
proposed for manufacturers to establish that their product is cost-effective and to
achieve revenue targets. UK payers will find it difficult to determine the level of
weighting applied to different unmet needs or to assign various rewards on value.
Respondents stated that PAS could be a method used to determine the level of
value through monitoring outcomes, but administrative burdens need to be con-
sidered. In the US, market evolution will accelerate the uptake of patient access
schemes. Taiwan is likely to introduce PAS approaches as a means to reduce ex-
penditure on high cost drugs. CONCLUSIONS: The current budget constraints in
the different countries may lead to an increased interest in implementing PAS,
which in turn may change the way health systems look at value for patients.
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WHICH CRITERIA ARE USED IN HEALTH CARE DECISIONMAKING AND
PRIORITY SETTING? A LITERATURE REVIEW FOR AN INTERNATIONAL SURVEY
OF DECISIONMAKERS
Guindo LA1, Wagner M2, Baltussen R3, Rindress D2, Van Til J4, Kind P5, Goetghebeur M2
1MSc Candidate, Montreal, QC, Canada, 2BioMedCom Consultants Inc., Dorval, QC, Canada,
3Radboud University, Nijmegen, The Netherlands, 4University of Twente, Enschede,
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OBJECTIVES: Resource allocation is one of the most challenging issues faced by
health policy decision-makers requiring efficient consideration of many factors.
Objectives of this study are to identify criteria used in decisionmaking around the
world. METHODS: An extensive literature search was performed in Medline and
EMBASE to identify articles reporting decision criteria. Bibliographies of relevant
articles were also searched. Studies conducted with healthcare decisionmakers
(e.g., empirical studies, field-testing of decisionmaking tools, focus groups, ques-
tionnaires, interviews), conceptual and reviews articles as well as articles describ-
ing decisionmaking tools were included. Criteria reported were extracted and or-
ganized using a classification system derived from the EVIDEM framework.
RESULTS: A total of 2903 records were identified through database searching and
243 additional records were identified through bibliographic hand searching; of
these 2790 were excluded. 356 articles were assessed for eligibility and 40 articles
were included in the study. Large variations in terminology used to defined criteria
were observed and 338 different terms were identified. These were assigned to 58
unique criteria which were classified in 9 different categories including: 1) health
outcomes and benefits of intervention, 2) types of health benefit, 3) impact of
disease targeted by intervention, 4) therapeutic context of intervention, 5) eco-
nomic impact of intervention, 6) quality/uncertainty of evidence, 7) implementa-
tion complexity of intervention, 8) priority, fairness and ethics, 9) overall context.
The most frequently mentioned criteria were: equity/fairness (33 times), efficacy/
effectiveness (28), healthcare stakeholder interests and pressures (28), cost-effec-
tiveness (23), strength of evidence (20), safety (19), mission and mandate of health
system (17), need (16), organizational requirements and capacity (17) and patient
reported outcomes (16). CONCLUSIONS: The data synthesized in this study will
serve as the basis for development of an international survey of healthcare deci-
sionmakers. The ultimate objective is to develop multicriteria approaches to effi-
cient healthcare decisionmaking and priority setting.
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COMPARATIVE EFFECTIVENESS REVIEWS AND THEIR POTENTIAL IMPACT ON
FORMULARY ACCESS IN THE UNITED STATES
Xia AD
HERON Evidence Development Ltd, London, UK
OBJECTIVES: The Effective Health Care Program of the AHRQ (Agency for Healthcare
Research and Quality) has sponsored various comparative effectiveness reviews. The
outcomes of these reviews were examined to determine their impact on access of
drugs in the US and potential future impact as the role of HTA becomes increasingly
important. METHODS: Initially, we examined the AHRQ online database and com-
piled a list of conclusions from completed comparative effectiveness reviews in vari-
ous therapy areas. Then, we compared these conclusions to the current access of
these therapies in a selection of the largest US plans by lines covered (Aetna, United-
Health, Cigna, Kaiser, Wellpoint) using their online formulary databases. RESULTS:
ACEIs vs. ARBs, NSAIDs, anti-depressants, epoetins, PPIs vs. H2As, and statins were
reviewed by the AHRQ. Some of these resultswere either inconsistent or inconclusive
due to lack of evidence; however, several found efficacy and safety to be similar across
agents in a class. As expected, access to these productswithin the largest US plans are
also comparable. In certain instances, a specific product or class demonstrated supe-
rior efficacy or tolerability. PPIs showed greater efficacy than H2As in resolution of
reflux disease, and more specifically, esomeprazole demonstrated superior efficacy
over omeprazole for relief of symptoms at 4 weeks. Topical NSAIDs, such as diclofe-
nac, demonstrated comparable efficacy to orals with fewer tolerability issues. How-
ever, these superiorities are not always reflected in the formulary access of these
products in terms of tier placement or restrictions. CONCLUSIONS: It appears that
these comparative effectiveness reviews by the AHRQ have some indirect impact on
formulary access in theUS.However, price and contracting, in addition to efficacy and
safety are among the key determinants for plans. It will be necessary to continue
monitoring these reviews moving forwards and attempt to filter out their direct im-
pact on access of drugs over time.
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CURRENT USES OF AND PERCEPTIONS ABOUT FDAMA SECTION 114
Lin PJ1, Hughes TE2, Neumann PJ1
1Tufts Medical Center, Boston, MA, USA, 2i3 Innovus, Carmel, IN, USA
OBJECTIVES: Section 114 of the 1997 U.S. Food and Drug Administration Moderniza-
tion Act (FDAMA) stipulates the conditions under which drug companies could pro-
mote health economic information to health care plans. This study examined current
uses of and perceptions about Section 114. METHODS: We conducted a web-based
surveyof a convenience sampleof 59experts representingpharmaceutical companies
and academia. We asked about their interpretation of, and experiences with, Section
114, as well as their views regarding the FDA issuing further guidance to advise phar-
maceutical companies onmaking promotional economic claims to payers. RESULTS:
Thirty-three of the 59 experts (56%) completed the survey. Among pharmaceutical
company health outcomes directors, 81% stated they always or frequently consider
using Section 114 when making promotional claims for drugs, but 63% stated they
were unclear about how to effectively create, approve or use Section 114 information.
The reasons for not using Section 114 included: not feeling comfortable using the
Section (25%); the fact that economic value information not included in the product
label (13%); and uncertainty aboutwhether creating a Section 114 piecewasworth the
benefit (13%). 75% expected to use Section 114 to a greater extent in the future. 75% of
outcomes director and 88% of academic experts stated that the FDA should issue
guidance on Section 114, especially regardingwhat qualifies as “health care economic
information” and “competent and reliable scientific evidence.” 69%of outcomesdirec-
tors and 65% of academic experts agreed that the increased focus on comparative
effectiveness research would increase Section 114 use. CONCLUSIONS: Pharmaceu-
tical companies are considering and using FDAMA Section 114 to make promotional
economic claims for drugs, despite their diverse interpretations of the law. Direction
from the FDA may clarify how companies could share a range of comparative eco-
nomic information with health plans.
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HOW ARE COVERAGE DECISIONS MADE IN PUBLICLY FUNDED HEALTH CARE
PROGRAMS IN LOW- AND MIDDLE-INCOME COUNTRIES?
Hornberger J, Shewade A, Gutierrez H
Cedar Associates LLC, Menlo Park, CA, USA
OBJECTIVES: Universal health coverage for all persons worldwide was the focus of
the First Global Symposium on Health Systems Research (Montreux, Switzerland;
Nov 2010). As part of a larger initiative sponsored by The Rockefeller Foundation to
transform health systems (accessible, affordable, equitable), we studied how cov-
erage decisions are made by publicly funded health care programs in low- and
middle-income countries (LMICs).METHODS: An online survey was administered
to representatives of 30 health care programs in LMICs. In-depth case studies,
based on ethnographic research methodologies, were conducted on a subset of
programs to address the following research questions: Who is covered in the pro-
gram? What health conditions and services are covered? What are the cultural,
political, ethical, scientific, and economic factors that influence coverage deci-
sions? What are the administrative processes for coverage decisions? What evi-
dence is used to determine coverage? What processes are used to monitor
outcomes? RESULTS: Maternal health, cardiovascular diseases, and preventing
catastrophic illness that results in large financial burden to the public tend to be the
highest priority conditions for coverage. Dental care and treatment for substance
abuse are the least commonly covered conditions.Most programsprovide coverage
for drugs; policies for drugs are basedmostly on published reports of clinical safety
and efficacy. Factors influencing decisions included limiting the financial risk from
catastrophic illness, ability to scale programs, and equity issues. Evidence used for
coverage decisions was based on medical literature, regional and global health
research, and coverage policies of other programs. Some programs undertake eco-
nomic appraisals and comparative effectiveness assessments in determining
policies. CONCLUSIONS: This ethnographic survey on how coverage policies are
being developed provides opportunities for LMICs to share their experiences with
each other, and thus further develop and refine their programs to meet goals of
accessible, affordable, and equitable heath care for all.
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DISPARITY IN ACCESS TO NOVEL DIABETIC AGENTS FOR MEDICARE PART D
ELDERLY COMPARED TO COMMERCIAL INSURED PATIENTS: INSIGHT INTO
DOWNSTREAM EFFECTS OF CMS FORMULARY COVERAGE GUIDELINES FOR
PDP’S
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